Nita K Patel
Overview
Explore the profile of Nita K Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
1003
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu Q, McLellan J, Kallewaard N, Ulbrandt N, Palaszynski S, Zhang J, et al.
Sci Transl Med
. 2017 May;
9(388).
PMID: 28469033
Prevention of respiratory syncytial virus (RSV) illness in all infants is a major public health priority. However, no vaccine is currently available to protect this vulnerable population. Palivizumab, the only...
2.
Gilman M, Moin S, Mas V, Chen M, Patel N, Kramer K, et al.
PLoS Pathog
. 2015 Jul;
11(7):e1005035.
PMID: 26161532
Prevention efforts for respiratory syncytial virus (RSV) have been advanced due to the recent isolation and characterization of antibodies that specifically recognize the prefusion conformation of the RSV fusion (F)...
3.
Robbie G, Criste R, DallAcqua W, Jensen K, Patel N, Losonsky G, et al.
Antimicrob Agents Chemother
. 2013 Oct;
57(12):6147-53.
PMID: 24080653
The study objective was to evaluate the pharmacokinetics (PK), antidrug antibody (ADA), and safety of motavizumab-YTE (motavizumab with amino acid substitutions M252Y/S254T/T256E [YTE]), an Fc-modified anti-respiratory syncytial virus (RSV) monoclonal...
4.
Zhu Q, Patel N, McAuliffe J, Zhu W, Wachter L, McCarthy M, et al.
J Infect Dis
. 2011 Dec;
205(4):635-8.
PMID: 22184728
Specific mutations in respiratory syncytial virus (RSV) fusion protein can cause palivizumab resistance. We assessed the incidence of sequence polymorphisms and palivizumab resistance in clinical RSV isolates collected from immunoprophylaxis-naive...
5.
Zhu Q, McAuliffe J, Patel N, Palmer-Hill F, Yang C, Liang B, et al.
J Infect Dis
. 2011 Jan;
203(5):674-82.
PMID: 21208913
Background: Palivizumab is a US Food and Drug Administration-approved monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory disease in high-risk infants. Motavizumab, derived from palivizumab with...
6.
Ulbrandt N, Ji H, Patel N, Barnes A, Wilson S, Kiener P, et al.
J Gen Virol
. 2008 Nov;
89(Pt 12):3113-3118.
PMID: 19008400
Human metapneumovirus (hMPV) is genetically related to respiratory syncytial virus (RSV); both cause respiratory tract illnesses ranging from a mild cough to bronchiolitis and pneumonia. The F protein-directed monoclonal antibody...
7.
Wu H, Pfarr D, Johnson S, Brewah Y, Woods R, Patel N, et al.
J Mol Biol
. 2007 Mar;
368(3):652-65.
PMID: 17362988
Respiratory syncytial virus (RSV) is the leading cause of viral bronchiolitis and pneumonia in infants and children. Currently, palivizumab is the only approved monoclonal antibody (mAb) for prophylaxis of RSV....
8.
Ulbrandt N, Ji H, Patel N, Riggs J, Brewah Y, Ready S, et al.
J Virol
. 2006 Jul;
80(16):7799-806.
PMID: 16873237
Human metapneumovirus (hMPV) is a recently described member of the Paramyxoviridae family/Pneumovirinae subfamily and shares many common features with respiratory syncytial virus (RSV), another member of the same subfamily. hMPV...
9.
Wu H, Pfarr D, Tang Y, An L, Patel N, Watkins J, et al.
J Mol Biol
. 2005 May;
350(1):126-44.
PMID: 15907931
We describe here the selection of ultra-potent anti-respiratory syncytial virus (RSV) antibodies for preventing RSV infection. A large number of antibody variants derived from Synagis (palivizumab), an anti-RSV monoclonal antibody...
10.
DeVincenzo J, Hall C, Kimberlin D, Sanchez P, Rodriguez W, Jantausch B, et al.
J Infect Dis
. 2004 Aug;
190(5):975-8.
PMID: 15295704
Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody,...